162 related articles for article (PubMed ID: 16310169)
1. Influence of heparin and dendrimers on the aggregation of two amyloid peptides related to Alzheimer's and prion diseases.
Klajnert B; Cortijo-Arellano M; Bryszewska M; Cladera J
Biochem Biophys Res Commun; 2006 Jan; 339(2):577-82. PubMed ID: 16310169
[TBL] [Abstract][Full Text] [Related]
2. Influence of phosphorus dendrimers on the aggregation of the prion peptide PrP 185-208.
Klajnert B; Cortijo-Arellano M; Cladera J; Majoral JP; Caminade AM; Bryszewska M
Biochem Biophys Res Commun; 2007 Dec; 364(1):20-5. PubMed ID: 17927954
[TBL] [Abstract][Full Text] [Related]
3. Molecular interactions of dendrimers with amyloid peptides: pH dependence.
Klajnert B; Cladera J; Bryszewska M
Biomacromolecules; 2006 Jul; 7(7):2186-91. PubMed ID: 16827586
[TBL] [Abstract][Full Text] [Related]
4. EPR study of the interactions between dendrimers and peptides involved in Alzheimer's and prion diseases.
Klajnert B; Cangiotti M; Calici S; Majoral JP; Caminade AM; Cladera J; Bryszewska M; Ottaviani MF
Macromol Biosci; 2007 Aug; 7(8):1065-74. PubMed ID: 17654761
[TBL] [Abstract][Full Text] [Related]
5. Amyloidogenic properties of the prion protein fragment PrP(185-208): comparison with Alzheimer's peptide Abeta(1-28), influence of heparin and cell toxicity.
Cortijo-Arellano M; Ponce J; Durany N; Cladera J
Biochem Biophys Res Commun; 2008 Apr; 368(2):238-42. PubMed ID: 18206983
[TBL] [Abstract][Full Text] [Related]
6. An autocatalytic reaction as a model for the kinetics of the aggregation of beta-amyloid.
Sabaté R; Gallardo M; Estelrich J
Biopolymers; 2003; 71(2):190-5. PubMed ID: 12767118
[TBL] [Abstract][Full Text] [Related]
7. Cell biology: infectious Alzheimer's disease?
Riek R
Nature; 2006 Nov; 444(7118):429-31. PubMed ID: 17122841
[No Abstract] [Full Text] [Related]
8. Branched KLVFF tetramers strongly potentiate inhibition of beta-amyloid aggregation.
Chafekar SM; Malda H; Merkx M; Meijer EW; Viertl D; Lashuel HA; Baas F; Scheper W
Chembiochem; 2007 Oct; 8(15):1857-64. PubMed ID: 17763487
[TBL] [Abstract][Full Text] [Related]
9. Amyloids, prions and the inherent infectious nature of misfolded protein aggregates.
Soto C; Estrada L; Castilla J
Trends Biochem Sci; 2006 Mar; 31(3):150-5. PubMed ID: 16473510
[TBL] [Abstract][Full Text] [Related]
10. Dense shell glycodendrimers as potential nontoxic anti-amyloidogenic agents in Alzheimer's disease. Amyloid-dendrimer aggregates morphology and cell toxicity.
Klementieva O; Benseny-Cases N; Gella A; Appelhans D; Voit B; Cladera J
Biomacromolecules; 2011 Nov; 12(11):3903-9. PubMed ID: 21936579
[TBL] [Abstract][Full Text] [Related]
11. Phosphorus dendrimers affect Alzheimer's (Aβ1-28) peptide and MAP-Tau protein aggregation.
Wasiak T; Ionov M; Nieznanski K; Nieznanska H; Klementieva O; Granell M; Cladera J; Majoral JP; Caminade AM; Klajnert B
Mol Pharm; 2012 Mar; 9(3):458-69. PubMed ID: 22206488
[TBL] [Abstract][Full Text] [Related]
12. Influence of dendrimer's structure on its activity against amyloid fibril formation.
Klajnert B; Cortijo-Arellano M; Cladera J; Bryszewska M
Biochem Biophys Res Commun; 2006 Jun; 345(1):21-8. PubMed ID: 16674918
[TBL] [Abstract][Full Text] [Related]
13. Investigation of the mechanism of beta-amyloid fibril formation by kinetic and thermodynamic analyses.
Lin MS; Chen LY; Tsai HT; Wang SS; Chang Y; Higuchi A; Chen WY
Langmuir; 2008 Jun; 24(11):5802-8. PubMed ID: 18452319
[TBL] [Abstract][Full Text] [Related]
14. Structure and function of amyloid in Alzheimer's disease.
Morgan C; Colombres M; Nuñez MT; Inestrosa NC
Prog Neurobiol; 2004 Dec; 74(6):323-49. PubMed ID: 15649580
[TBL] [Abstract][Full Text] [Related]
15. Delineating common molecular mechanisms in Alzheimer's and prion diseases.
Barnham KJ; Cappai R; Beyreuther K; Masters CL; Hill AF
Trends Biochem Sci; 2006 Aug; 31(8):465-72. PubMed ID: 16820299
[TBL] [Abstract][Full Text] [Related]
16. Fitting yeast and mammalian prion aggregation kinetic data with the Finke-Watzky two-step model of nucleation and autocatalytic growth.
Watzky MA; Morris AM; Ross ED; Finke RG
Biochemistry; 2008 Oct; 47(40):10790-800. PubMed ID: 18785757
[TBL] [Abstract][Full Text] [Related]
17. Conversion of non-fibrillar beta-sheet oligomers into amyloid fibrils in Alzheimer's disease amyloid peptide aggregation.
Benseny-Cases N; Cócera M; Cladera J
Biochem Biophys Res Commun; 2007 Oct; 361(4):916-21. PubMed ID: 17679138
[TBL] [Abstract][Full Text] [Related]
18. Fitting neurological protein aggregation kinetic data via a 2-step, minimal/"Ockham's razor" model: the Finke-Watzky mechanism of nucleation followed by autocatalytic surface growth.
Morris AM; Watzky MA; Agar JN; Finke RG
Biochemistry; 2008 Feb; 47(8):2413-27. PubMed ID: 18247636
[TBL] [Abstract][Full Text] [Related]
19. High-resolution NMR studies of the zinc-binding site of the Alzheimer's amyloid beta-peptide.
Danielsson J; Pierattelli R; Banci L; Gräslund A
FEBS J; 2007 Jan; 274(1):46-59. PubMed ID: 17222176
[TBL] [Abstract][Full Text] [Related]
20. Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease.
Rodríguez-Rodríguez C; Sánchez de Groot N; Rimola A; Alvarez-Larena A; Lloveras V; Vidal-Gancedo J; Ventura S; Vendrell J; Sodupe M; González-Duarte P
J Am Chem Soc; 2009 Feb; 131(4):1436-51. PubMed ID: 19133767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
